Alzheimer’s Foundation of America Statement on FDA Granting Traditional Approval of New Alzheimer’s Medication
(July 6, 2023)- “Today, we are encouraged that the FDA’s traditional approval of lecanemab will make a positive difference in the lives of individuals and families affected by Alzheimer’s disease. Progress is being made in the fight against Alzheimer’s disease, but we must continue moving forward until the finish line of finding a cure for Alzheimer’s disease is reached.
“Patient access and affordability to all of those in need is vitally important, as with any medication, and we hope the FDA’s actions will facilitate both. We strongly urge federal policy makers to continue increasing investments in Alzheimer’s disease research and caregiver support services to deliver help today and hope for the future to the more than 6 million American families affected by Alzheimer’s disease.”
